Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice.


Autoria(s): Thorel F.; Damond N.; Chera S.; Wiederkehr A.; Thorens B.; Meda P.; Wollheim C.B.; Herrera P.L.
Data(s)

2011

Resumo

OBJECTIVEEvaluate whether healthy or diabetic adult mice can tolerate an extreme loss of pancreatic α-cells and how this sudden massive depletion affects β-cell function and blood glucose homeostasis.RESEARCH DESIGN AND METHODSWe generated a new transgenic model allowing near-total α-cell removal specifically in adult mice. Massive α-cell ablation was triggered in normally grown and healthy adult animals upon diphtheria toxin (DT) administration. The metabolic status of these mice was assessed in 1) physiologic conditions, 2) a situation requiring glucagon action, and 3) after β-cell loss.RESULTSAdult transgenic mice enduring extreme (98%) α-cell removal remained healthy and did not display major defects in insulin counter-regulatory response. We observed that 2% of the normal α-cell mass produced enough glucagon to ensure near-normal glucagonemia. β-Cell function and blood glucose homeostasis remained unaltered after α-cell loss, indicating that direct local intraislet signaling between α- and β-cells is dispensable. Escaping α-cells increased their glucagon content during subsequent months, but there was no significant α-cell regeneration. Near-total α-cell ablation did not prevent hyperglycemia in mice having also undergone massive β-cell loss, indicating that a minimal amount of α-cells can still guarantee normal glucagon signaling in diabetic conditions.CONCLUSIONSAn extremely low amount of α-cells is sufficient to prevent a major counter-regulatory deregulation, both under physiologic and diabetic conditions. We previously reported that α-cells reprogram to insulin production after extreme β-cell loss and now conjecture that the low α-cell requirement could be exploited in future diabetic therapies aimed at regenerating β-cells by reprogramming adult α-cells.

Identificador

https://serval.unil.ch/?id=serval:BIB_16B62B557AAA

isbn:1939-327X (Electronic)

pmid:21926270

doi:10.2337/db11-0876

isiid:000296954600026

http://my.unil.ch/serval/document/BIB_16B62B557AAA.pdf

http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_16B62B557AAA7

Idioma(s)

en

Direitos

info:eu-repo/semantics/openAccess

Fonte

Diabetes, vol. 60, no. 11, pp. 2872-2882

Palavras-Chave #Animals; Apoptosis/drug effects; Cell Count; Diabetes Mellitus, Experimental/blood; Diabetes Mellitus, Experimental/chemically induced; Diphtheria Toxin/toxicity; Glucagon/blood; Glucagon/genetics; Glucagon-Secreting Cells/drug effects; Glucagon-Secreting Cells/metabolism; Hyperglycemia/chemically induced; Hyperglycemia/prevention & control; Hypoglycemia/prevention & control; Insulin/blood; Insulin/metabolism; Insulin-Secreting Cells/drug effects; Insulin-Secreting Cells/metabolism; Intercellular Signaling Peptides and Proteins/genetics; Intercellular Signaling Peptides and Proteins/metabolism; Male; Mice; Mice, Transgenic; Pancreas/drug effects; Pancreas/metabolism; Promoter Regions, Genetic; Receptors, Glucagon/metabolism; Selective Estrogen Receptor Modulators/pharmacology; Signal Transduction; Streptozocin/toxicity; Tamoxifen/pharmacology
Tipo

info:eu-repo/semantics/article

article